ReviewDrugs2001
Current management of fungal infections.
Review in Drugs, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 98 citations in OpenAlex.
- Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.Antimicrobial agents and chemotherapy · 2006Trial
- Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.Antimicrobial agents and chemotherapy · 2006Trial
- Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects.British journal of clinical pharmacology · 2004Trial
- Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.British journal of clinical pharmacology · 2003Trial
- Emerging Trends in the Use of Topical Antifungal-Corticosteroid Combinations.Journal of fungi (Basel, Switzerland) · 2022Review
- Efficacy of antifungal agents against fungal spores: An in vitro study using microplate laser nephelometry and an artificially infected 3D skin model.MicrobiologyOpen · 2022Article
- New perspectives on the topical management of recurrent candidiasis.Drug delivery and translational research · 2021Review
- Transcriptome Analyses ofG3 (Bethesda, Md.) · 2020Article
- Metal (II) Complexes of Fluconazole: Thermal, XRD and Cytotoxicity Studies.Iranian journal of pharmaceutical research : IJPR · 2020Article
- Determining the optimal parameters of 420-nm intense pulsed light on Trichophyton rubrum growth in vitro.Lasers in medical science · 2018Article
- The Role of NADPH Oxidase in the Inhibition ofFrontiers in microbiology · 2017Article
- Identification of Candida species in patients with oral lesion undergoing chemotherapy along with minimum inhibitory concentration to fluconazole.Advanced biomedical research · 2016Article
- In vitro combination therapy using low dose clotrimazole and photodynamic therapy leads to enhanced killing of the dermatophyte Trichophyton rubrum.BMC microbiology · 2014Article
- Itraconazole, a commonly used antifungal, inhibits Fcγ receptor-mediated phagocytosis: alteration of Fcγ receptor glycosylation and gene expression.Shock (Augusta, Ga.) · 2014Article
- Oral complications and management strategies for patients undergoing cancer therapy.TheScientificWorldJournal · 2014Review
- Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.Current drug metabolism · 2013Review
- Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.BioMed research international · 2013Review
- Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability.AAPS PharmSciTech · 2012Article
- Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus.Molecular ecology · 2012Article
- [Anti-fungal drugs. Current status and guidelines for their administration].Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of superficial fungal infections differs significantly from the management of systemic fungal infections. Most superficial infections are treated with topical antifungal agents, the choice of agent being determined by the site and extent of the infection and by the causative organism, which is usually readily identifiable. One exception is onychomycosis, which usually requires treatment with systemically available antifungals; the accumulation of terbinafine and itraconazole in keratinous tissues makes them ideal agents for the treatment of onychomycosis. Oral candidiasis in immunocompromised patients also requires systemic treatment; oral fluconazole and itraconazole oral solution are highly effective in this setting. Systemic fungal infections are difficult to diagnose and are usually managed with prophylaxis or empirical therapy. Fluconazole and itraconazole are widely used in chemoprophylaxis because of their favourable oral bioavailability and safety profiles. In empirical therapy, lipid-associated formulations of amphotericin-B and intravenous itraconazole are safer than, and at least as effective as, conventional amphotericin-B (the former gold standard). The high acquisition costs of the lipid-associated formulations of amphotericin-B have limited their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.